Ping An Securities released a research report on April 23 stating that it gave Yuandong Biology (688513.SH) a recommended rating. The main reasons for the rating include: 1) the company's collection risk is basically clear; 2) the refined hemp specialty innovation pipeline continues to advance, which is expected to usher in intensive catalysis in the short to medium term; 3) specialty hemp injections go overseas, driving the company's long-term growth. (Mainichi Keizai Shimbun)
平安证券4月23日发布研报称，给予苑东生物（688513.SH）推荐评级。评级理由主要包括：1）公司集采风险基本出清，精麻大单品放量确定性较强；2）精麻特色创新管线持续推进，中短期有望迎来密集催化；3）精麻特色注射剂出海，驱动公司长期成长。（每日经济新闻）
Ping An Securities released a research report on April 23 stating that it gave Yuandong Biology (688513.SH) a recommended rating. The main reasons for the rating include: 1) the company's collection risk is basically clear; 2) the refined hemp specialty i
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.